REGNRegeneron Pharmaceuticals Inc — stock analysis & sentiment

At $834.04, Regeneron is trading close to the upper end of its 52-week range of $541 to $847 — within about 2% of the high, and roughly 54% above the low. A band that wide over a single year points to a stock that has re-rated substantially rather than drifting, with the bulk of the distance covered on the way back up toward where it now sits.

Against that, the market is paying about 20.6 times trailing earnings and 2.6 times book for a business carrying a 27.9% profit margin and 16.7% revenue growth. The forward multiple of 13.8 is well below the trailing figure, meaning consensus expects earnings to rise from here; the gap between the two is the clearest thing the valuation data says. A beta of 0.188 is unusually low, indicating the shares have historically moved largely independently of the broader market rather than amplifying it, and the company pays only a token dividend, so essentially all of the return profile has come from the price itself.

The recent news flow is almost entirely company-specific and legal in character. Seven of the eight most recent items are securities class action notices from separate plaintiffs' firms — Hagens Berman, Schall, Bronstein Gewirtz & Grossman, Portnoy, and BFA — filed between late July and early August 2026, with the announcements referencing disclosures around a key trial's protocol and its ultimate failure. Only one item, a comparison of two biotech ETFs, is sector-level rather than about Regeneron directly. Readers should note that class action filings are allegations at this stage, and the coverage reflects law firm announcements rather than adjudicated findings.